Medtronic shares rated 'Buy' with 10%+ upside after strong Q4 growth and solid FY 2027 outlook.
Medtronic is reaffirmed as a 'Buy' with shares expected to gain over 10% based on strong fundamentals and attractive valuation. The company posted its best organic revenue growth in a decade at 6.6% in Q4, driven by double-digit growth in its Cardiov...
